Salivary Gland Tumor Fusion Panel with Interpretation
Label Mnemonic: | SGTF |
Epic code: | LAB8690 |
Downtime form: | A-1a Doctor-Provider Orders - Pathology Microbiology |
Molecular Pathology
6240 RCP
384-9568
6240 RCP
384-9568
Specimen(s):
Formalin-fixed, paraffin embedded tissue block, or 10 unstained 4 micron-thick section on non-plus slides and one H&E stained section or Fine needle aspirate
Rejection Criteria:
Specimens that have been decalcified will not be accepted.
Testing Schedule:
Weekly
Turn Around
Time:
21 days
Reference Range:
Fusion or mutation not detected.
Interpretive Data:
Detected
Not detected
Not detected
Comments:
Tissue sections are reviewed by a pathologist. RNA is isolated from
the selected area of the sample. Anchored multiplex PCR for a targeted
next-generation sequencing is performed. The sequenced sample is a
reverse transcription PCR-amplified fragenbt library in which each
sample is uniquely identified by ligation of a short oligonucleotide
barcode. The resultant sequence identifies the exons of the fusion
transcript arising from the specific gene target and the partnet
gene.
The panel target gene rearrangements of these gene targets: ETV6, EWSR1, HMGA2, HRAS, MAML2, MYB, MYBL1, NFIB, NTRK3, NUTM1, PLAG1, PRKD1, PRKD2, PRKD3.
The panel target gene rearrangements of these gene targets: ETV6, EWSR1, HMGA2, HRAS, MAML2, MYB, MYBL1, NFIB, NTRK3, NUTM1, PLAG1, PRKD1, PRKD2, PRKD3.
Methodology:
Massively paraellel Next Generation RNA sequencing by synthesis,
semiconductor technology, Illumia
CPT Code:
81445